关键词: 组织工程化口腔黏膜, HBD-2, HBD-3, 免疫防御

Abstract: PURPOSE: To investigate the expression of human beta-defensin 2(HBD-2) and human beta-defensin 3 (HBD-3) in tissue engineered oral mucosa equivalents under the stimulation of Escherichia coli lipopolysaccharide (LPS) and recombinant human interleukin-1(IL-1β), and to evaluate the possibility of using tissue engineered oral mucosa in the treatment of infectious oral diseases. METHODS: Real-time fluorescent quantitative reverse transcription PCR(RT-qPCR) and Western blot were used to evaluate the mRNA and protein expression of HBD-2 and HBD-3 in tissue engineered oral mucosa substitutes under the stimulation of LPS and IL-1β. SPSS 26.0 software package was used for data analysis. RESULTS: LPS and IL-1β stimulated the mRNA and protein expression of HBD-2 and HBD-3 in tissue-engineered oral mucosa, and showed a dose-dependent increase after 24 hours of culture(P<0.05). At 100 ng/mL, LPS induced HBD-2 mRNA by about 2.7-fold and HBD-3 mRNA by about 5-fold, respectively. The maximal production of HBD-2 mRNA was about 1.6-fold and HBD-3 about 4.8-fold by 20 ng/mL IL-1β. As to the results of western blot analysis, both LPS and IL-1β induced HBD-2 protein secretion at the maximal concentration in this study. HBD-3 protein was hardly observed without any treatment. After incubation with LPS and IL-1β, HBD-3 protein was significantly up-regulated(P<0.05). CONCLUSIONS: Tissue engineered oral mucosa equivalents are armed with defense activity against invading microorganisms in a sense, which may provide a therapy substitute for infectious oral diseases in the future.

Key words: Tissue engineered oral mucosa, HBD-2, HBD-3, Immune defense